Asia-Pacific Autoimmune Monoclonal Antibodies Market By Source (Murine, Chimeric, Humanized, & Human), By Application (Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Transplant Rejection/Graft Versus Host Disease, & Others), and By End User (Hospitals/Clinics, Research Institutes, & Diagnostic Laboratories) – Market Analysis, Size, Geographic Countries Analysis, Competitive Strategies Analysis and Forecasts (2016 to 2021)

Asia-Pacific Autoimmune Monoclonal Antibodies Market By Source (Murine, Chimeric, Humanized, & Human), By Application (Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Transplant Rejection/Graft Versus Host Disease, & Others), and By End User (Hospitals/Clinics, Research Institutes, & Diagnostic Laboratories) – Market Analysis, Size, Geographic Countries Analysis, Competitive Strategies Analysis and Forecasts (2016 to 2021)

ID: 1173 | Pages: 140 | November 2016 | Region: Asia Pacific


Asia-Pacific Autoimmune Monoclonal Antibodies market is expected to reach USD 2,181.4 million by 2021 from USD 1,559.7 million in 2016, growing at a CAGR of 6.94% during forecast period 2016-2021. Irregular functioning of humans’ immune system results in autoimmune disorders. Overproduction of self-reactive immune cells (such as antibodies & T-cells) damage regular functions of /cells/tissues/organs. This lead to different autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and others diseases. Typically, drugs are used as a treatment to cure autoimmune disorders. The adverse effects associated with drugs has made switched to concentrate on monoclonal antibodies.

Monoclonal antibodies have the ability to offer less toxic and more efficient therapeutic alternatives to treat autoimmune diseases. Recent years have seen the emergence of monoclonal antibodies being used to treat wide array of diseases that are related to immune response. These antibodies are mono-specific comprising of identical immune cells which are clones of a single parent cell and are directed towards a specific cellular target. Thus monoclonal antibodies due to its customizable nature can be used to treat the self-reactive immune cells not impacting the normal ones.

Rising healthcare expenditure, increasing disease patient population associated with lifestyle changes, growing involvement of universities & research institutes, rising demand for advanced healthcare therapeutics, and presence of huge population are driving the growth of autoimmune monoclonal antibodies market in Asia-Pacific. However, low adoption of advanced therapies, high cost of monoclonal antibodies therapeutics, and lack of superior research facilities in certain Asian countries are restraining the growth of autoimmune monoclonal antibodies market in Asia-Pacific.

Asia-Pacific Autoimmune Monoclonal Antibodies market is segmented based on source, application, and end user. Based on source, the market is further sub-segmented as Murine, Chimeric, Humanized, and Human. Among these, humanized segment is expected to command the largest share in Asia-Pacific Autoimmune Monoclonal Antibodies market, by source in 2016. Based on application, the market is further segmented as Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Transplant Rejection/Graft Versus Host Disease, and Others. Of these, rheumatoid arthritis application is anticipated to command the major share in Asia-Pacific Autoimmune Monoclonal Antibodies market, by application in 2016. Based on end user, the market is further segmented as Hospitals/Clinics, Research Institutes, and Diagnostic Laboratories. Among these, Hospitals/Clinics segment is expected to hold the major market share in Asia-Pacific Autoimmune Monoclonal Antibodies market, by application in 2016.

On the basis of geographical areas, Asia-Pacific Autoimmune Monoclonal Antibodies market is segmented as Japan, China, India, South Korea, and Australia.

The key players in Autoimmune Monoclonal Antibodies market include, GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Innovent Biologics, Inc. (China), Takeda Pharmaceutical Company Ltd. (Japan), Amgen Inc. (U.S.), Biogen Inc.(U.S.), and UCB Company (Belgium).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Source                    

                                5.1.1 Murine     

                                5.1.2 Chimeric  

                                5.1.3 Humanized             

                                5.1.4 Human     

                5.2 By Application                           

                                5.2.1 Systemic Lupus Erythematosus      

                                5.2.2 Rheumatoid Arthritis          

                                5.2.3 Multiple Sclerosis 

                                5.2.4 Transplant Rejection/Graft Versus Host Disease     

                                5.2.5 Others      

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

6. Geographical Analysis                                              

                6.1 Asia-Pacific                 

                                6.1.1 Introduction           

                                6.1.2 China         

                                6.1.3 India          

                                6.1.4 Japan        

                                6.1.5 South Korea           

                                6.1.6 Australia  

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Monoclonal Antibodies Development                 

                                7.5.1 Targeted Therapies             

                7.6 Promising Monoclonal Antibodies in Pipeline                              

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies                   

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 GlaxoSmithKline plc (U.K.)                   

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 AstraZeneca plc (U.K.)                           

                9.6 Innovent Biologics, Inc. (China)                          

                9.4 Bristol-Myers Squibb (U.S.)                 

                9.5 Johnson & Johnson (U.S.)                    

                9.6 Innovent Biologics, Inc. (China)                          

                9.7 Takeda Pharmaceutical Company Ltd. (Japan)                             

                9.8 Amgen Inc. (U.S.)                     

                9.9 Biogen Inc.(U.S.)                      

                9.10 UCB Company (Belgium)                    

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Asia-Pacific Autoimmune Monoclonal Antibodies Market By Region, From 2016-2021 ( USD Million )
  2. Asia-Pacific Autoimmune Monoclonal Antibodies Market By Source, From 2016-2021 ( USD Million )
  3. Asia-Pacific Murine Monoclonal Antibodies Market By Region, From 2016-2021 ( USD Million )
  4. Asia-Pacific Chimeric Monoclonal Antibodies Market By Region, From 2016-2021 ( USD Million )
  5. Asia-Pacific Humanized Monoclonal Antibodies Market By Region, From 2016-2021 ( USD Million )
  6. Asia-Pacific Human Monoclonal Antibodies Market By Region, From 2016-2021 ( USD Million )
  7. Asia-Pacific Autoimmune Monoclonal Antibodies Market By Application, From 2016-2021 ( USD Million )
  8. Asia-Pacific Systemic Lupus Erythematosus Market By Region, From 2016-2021 ( USD Million )
  9. Asia-Pacific Rheumatoid Arthritis Market By Region, From 2016-2021 ( USD Million )
  10. Asia-Pacific Multiple Sclerosis Market By Region, From 2016-2021 ( USD Million )
  11. Asia-Pacific Transplant Rejection/Graft Versus Host Disease Market By Region, From 2016-2021 ( USD Million )
  12. Asia-Pacific Other Applications Market By Region, From 2016-2021 ( USD Million )
  13. Asia-Pacific Autoimmune Monoclonal Antibodies Market By End User, From 2016-2021 ( USD Million )
  14. Asia-Pacific Hospitals/Clinics Market By Region, From 2016-2021 ( USD Million )
  15. Asia-Pacific Research Institute Market By Region, From 2016-2021 ( USD Million )
  16. Asia-Pacific Diagnostic Laboratories Market By Region, From 2016-2021 ( USD Million )
  17. China Autoimmune Monoclonal Antibodies Market By Source, From 2016-2021 ( USD Million )
  18. China Autoimmune Monoclonal Antibodies Market By Application, From 2016-2021 ( USD Million )
  19. China Autoimmune Monoclonal Antibodies Market By End User, From 2016-2021 ( USD Million )
  20. India Autoimmune Monoclonal Antibodies Market By Source, From 2016-2021 ( USD Million )
  21. India Autoimmune Monoclonal Antibodies Market By Application, From 2016-2021 ( USD Million )
  22. India Autoimmune Monoclonal Antibodies Market By End User, From 2016-2021 ( USD Million )
  23. Japan Autoimmune Monoclonal Antibodies Market By Source, From 2016-2021 ( USD Million )
  24. Japan Autoimmune Monoclonal Antibodies Market By Application, From 2016-2021 ( USD Million )
  25. Japan Autoimmune Monoclonal Antibodies Market By End User, From 2016-2021 ( USD Million )
  26. South Korea Autoimmune Monoclonal Antibodies Market By Source, From 2016-2021 ( USD Million )
  27. South Korea Autoimmune Monoclonal Antibodies Market By Application, From 2016-2021 ( USD Million )
  28. South Korea Autoimmune Monoclonal Antibodies Market By End User, From 2016-2021 ( USD Million )
  29. Australia Autoimmune Monoclonal Antibodies Market By Source, From 2016-2021 ( USD Million )
  30. Australia Autoimmune Monoclonal Antibodies Market By Application, From 2016-2021 ( USD Million )
  31. Australia Autoimmune Monoclonal Antibodies Market By End User, From 2016-2021 ( USD Million )
Middle East And Africa Non-Surgical Skin Tightening Market By Product (Laser-based Devices, RF Devices, Ultrasound Devices, And Other Devices), End User (Dermatology Clinics, And Beauty Clinics), And Region - Indust...
Latin America Non-Surgical Skin Tightening Market By Product (Laser-based Devices, RF Devices, Ultrasound Devices, And Other Devices), End User (Dermatology Clinics, And Beauty Clinics), And Region - Industry Analys...
Asia Pacific Non-Surgical Skin Tightening Market By Product (Laser-based Devices, RF Devices, Ultrasound Devices, And Other Devices), End User (Dermatology Clinics, And Beauty Clinics), And Region - Industry Analysi...
North America Non-Surgical Skin Tightening Market By Product (Laser-based Devices, RF Devices, Ultrasound Devices, And Other Devices), End User (Dermatology Clinics, And Beauty Clinics), And Region - Industry Analys...
Non-Surgical Skin Tightening Market By Product (Laser-based Devices, RF Devices, Ultrasound Devices, And Other Devices), End User (Dermatology Clinics, And Beauty Clinics), And Region - Global Industry Analysis, Siz...
Middle East And Africa Pigmented Lesion Treatment Market By Product (Energy Based Devices, RF Devices, Ultrasound Devices, IPL Devices), End User (Beauty Clinics, Dermatology Clinics), And Region - Industry Analysis...
Latin America Pigmented Lesion Treatment Market By Product (Energy Based Devices, RF Devices, Ultrasound Devices, IPL Devices), End User (Beauty Clinics, Dermatology Clinics), And Region - Industry Analysis, Size, S...
Asia Pacific Pigmented Lesion Treatment Market By Product (Energy Based Devices, RF Devices, Ultrasound Devices, IPL Devices), End User (Beauty Clinics, Dermatology Clinics), And Region - Industry Analysis, Size, Sh...
Europe Pigmented Lesion Treatment Market By Product (Energy Based Devices, RF Devices, Ultrasound Devices, IPL Devices), End User (Beauty Clinics, Dermatology Clinics), And Region - Industry Analysis, Size, Share, G...
North America Pigmented Lesion Treatment Market By Product (Energy Based Devices, RF Devices, Ultrasound Devices, IPL Devices), End User (Beauty Clinics, Dermatology Clinics), And Region - Industry Analysis, Size, S...
Pigmented Lesion Treatment Market By Product (Energy Based Devices, RF Devices, Ultrasound Devices, IPL Devices), End User (Beauty Clinics, Dermatology Clinics), And Region - Global Industry Analysis, Size, Share, G...
Middle East And Africa Dermal Fillers Market By Product (Absorbable Or Biodegradable, Non-Absorbable Or Non-Biodegradable), Therapeutic Area (Wrinkles, Deep Facial Lines, Sagging Skin, Scars), And Region -Industry A...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.